Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature.

Publisher: BioMed Central Country of Publication: England NLM ID: 101251558 Publication Model: Electronic Cited Medium: Internet ISSN: 1746-1596 (Electronic) Linking ISSN: 17461596 NLM ISO Abbreviation: Diagn Pathol Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2006-

Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/genetics ; Lung Neoplasms*/drug therapy ; Lung Neoplasms*/genetics ; Kidney Diseases, Cystic*/chemically induced ; Kidney Diseases, Cystic*/diagnosis ; Kidney Diseases, Cystic*/genetics ; Cysts*/chemically induced; Humans ; Female ; Aged ; Crizotinib/adverse effects ; Anaplastic Lymphoma Kinase/genetics

Background: Crizotinib, an oral first-generation tyrosine kinase inhibitor (TKI), is superior to systemic chemotherapy for the treatment of non-small cell lung cancer (NSCLC) with positive rearrangement of anaplastic lymphoma kinase (ALK). However, an increased incidence of renal and hepatic cysts has been reported in the patients on crizotinib treatment.
Case Presentation: Here, we describe a case of a 71-year-old Chinese women developed multiple cystic lesions in kidney and liver during crizotinib treatment for the primary and metastatic NSCLC. The renal and hepatic cysts were noted by CT scan 3 months after crizotinib treatment, which were spontaneously and significantly regressed after stopping crizotinib.
Conclusions: Based on literature review and our experience in this case report, we concluded that crizotinib-associated renal cyst (CARCs) has features of malignancy and abscess in radiographic imaging, and thus, pathological confirmation is necessary to avoid inappropriate treatment decision. In addition, to benefit the patients with progress-free survival (PFS), switching from crizotinib to alectinib is recommended for the treatment of NSCLC patients who developed CARCs.
(© 2024. The Author(s).)

BMJ Case Rep. 2015 Sep 08;2015:. (PMID: 26351314)
J Cancer Res Clin Oncol. 2021 Dec;147(12):3769-3771. (PMID: 34373943)
J Urol. 2004 Jun;171(6 Pt 1):2166-70. (PMID: 15126778)
Urol Int. 2020;104(3-4):269-272. (PMID: 31480046)
J Thorac Oncol. 2009 Dec;4(12):1450-4. (PMID: 20009909)
ESMO Open. 2017 Aug 17;2(3):e000219. (PMID: 29209525)
Radiol Case Rep. 2016 May 18;11(3):245-7. (PMID: 27594959)
Chronic Dis Transl Med. 2017 Jul 19;3(3):148-153. (PMID: 29063069)
Urology. 2018 Nov;121:e3-e4. (PMID: 30142403)
Int J Mol Sci. 2018 Sep 25;19(10):. (PMID: 30257437)
Ann Oncol. 2005;16 Suppl 1:i28-9. (PMID: 15888743)
Ther Adv Med Oncol. 2015 Sep;7(5):274-90. (PMID: 26327925)
Insights Imaging. 2015 Aug;6(4):479-87. (PMID: 26162467)
Urology. 2019 Sep;131:21-23. (PMID: 31078629)
Drug Saf. 2019 Feb;42(2):211-233. (PMID: 30649748)
Lancet Oncol. 2015 Apr;16(4):e165-72. (PMID: 25846096)
PLoS One. 2018 Oct 23;13(10):e0205827. (PMID: 30352060)
Int J Mol Sci. 2022 May 21;23(10):. (PMID: 35628598)
Case Rep Oncol. 2022 Mar 30;15(1):338-344. (PMID: 35529295)
Front Oncol. 2022 Jul 07;12:920990. (PMID: 35875128)
Kidney Int Rep. 2016 Sep 21;2(1):108-123. (PMID: 29318210)
Clin Imaging. 2020 Sep;65:15-17. (PMID: 32353713)
Intern Med. 2017 Sep 1;56(17):2321-2324. (PMID: 28794366)
N Engl J Med. 2014 Dec 4;371(23):2167-77. (PMID: 25470694)
Cancer Imaging. 2017 Feb 16;17(1):7. (PMID: 28209203)
Clin Case Rep. 2021 Jun 10;9(6):e04278. (PMID: 34136235)
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342)
Oncologist. 2014 Sep;19(9):1008-10. (PMID: 25096999)
J Med Chem. 2011 Sep 22;54(18):6342-63. (PMID: 21812414)
N Engl J Med. 2013 Jun 20;368(25):2385-94. (PMID: 23724913)
Nature. 2007 Aug 2;448(7153):561-6. (PMID: 17625570)
Lancet. 1994 Sep 17;344(8925):789-91. (PMID: 7916076)
Curr Oncol. 2022 Mar 14;29(3):1967-1982. (PMID: 35323360)
Radiology. 2005 Aug;236(2):441-50. (PMID: 16040900)
J Thorac Oncol. 2014 Nov;9(11):1720-5. (PMID: 25436806)
Int Med Case Rep J. 2020 Mar 16;13:89-93. (PMID: 32214855)
N Engl J Med. 2010 Oct 28;363(18):1693-703. (PMID: 20979469)
Cancer Med. 2015 Jun;4(6):887-96. (PMID: 25756473)
South Asian J Cancer. 2013 Apr;2(2):91-7. (PMID: 24455567)

Keywords: Case report; Crizotinib; Crizotinib-associated renal cyst; Non-small cell lung cancer

53AH36668S (Crizotinib)
EC 2.7.10.1 (Anaplastic Lymphoma Kinase)

Date Created: 20240414 Date Completed: 20240416 Latest Revision: 20240425

20240425

PMC11016210

10.1186/s13000-024-01480-7

38616252